Yu-Hsiang Lee, DO
Family Medicine · Monterey Park, CANPI 1245262013
Payments from drug & device makers
Across 636 payments — averaging $116.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cleerly, Inc.$55K
- AstraZeneca$2K
- Merz North America, Inc.$2K
- Amgen$2K
- AbbVie$2K
- GSK$1K
- plus $9K from 28 others
What the payments were for
- Travel & lodging$1,4958%
- Food & beverage$17,74992%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cleerly, Inc. | 7 | $54,825 |
| AstraZeneca | 58 | $2,459 |
| Merz North America, Inc. | 13 | $2,375 |
| Amgen | 102 | $2,308 |
| AbbVie(2 entities) | 57 | $1,814 |
| GSK | 46 | $1,391 |
| Lilly USA, LLC | 48 | $1,375 |
| Boehringer Ingelheim | 62 | $1,359 |
| Novo Nordisk | 54 | $1,252 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $683 |
| Bayer | 25 | $624 |
| Amarin Pharma, Inc. | 31 | $588 |
| Novartis | 23 | $568 |
| Nestle Healthcare Nutrition Inc. | 15 | $376 |
| Vivus LLC | 6 | $326 |
| Aimmune Therapeutics, Inc. | 8 | $205 |
| Gilead | 7 | $183 |
| Exact Sciences | 7 | $176 |
| Kowa Pharmaceuticals America, Inc. | 9 | $172 |
| Johnson & Johnson | 2 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $145 |
| Pfizer | 6 | $138 |
| Corium, LLC | 6 | $124 |
| Eisai Inc. | 6 | $99 |
| Merck | 4 | $90 |
| Redhill Biopharma Inc. | 3 | $64 |
| Biohaven Pharmaceuticals, Inc. | 2 | $51 |
| Radius Health, Inc. | 2 | $48 |
| Sanofi Pasteur Inc. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Exeltis, USA Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Electromed, Inc. | 1 | $19 |
| Biogen | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$74,105 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 81 | $124,890 |
| ProliaDenosumab | 54 | $88,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $86,146 |
| VascepaIcosapent Ethyl | 177 | $81,080 |
| ZenpepLipase/Protease/Amylase | 38 | $69,286 |
| JardianceEmpagliflozin | 94 | $68,849 |
| OzempicSemaglutide | 57 | $58,625 |
| RestasisCyclosporine | 52 | $40,540 |
| KerendiaFinerenone | 41 | $31,874 |
| RybelsusSemaglutide | 20 | $31,733 |
| Icosapent Ethyl | 105 | $30,272 |
| TradjentaLinagliptin | 53 | $29,483 |
| JanuviaSitagliptin Phosphate | 37 | $24,482 |
| Repatha SureclickEvolocumab | 45 | $24,182 |
| MounjaroTirzepatide | 20 | $23,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Restasis, Linzess | $1,814 | $182,908163 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat, Synjardy | $1,359 | $129,281204 claims |
| Novo NordiskOzempic, Rybelsus | $1,252 | $90,35877 claims |
| AmgenProlia | $2,308 | $88,51454 claims |
| GSKTrelegy Ellipta | $1,391 | $86,146135 claims |
| Aimmune Therapeutics, Inc.Zenpep | $205 | $69,28638 claims |
| MerckJanuvia, Janumet | $90 | $47,38575 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,375 | $36,15833 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,459 | $35,55349 claims |
| BayerKerendia | $624 | $31,87441 claims |
| PfizerEliquis | $138 | $10,23218 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $172 | $4,18611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Monterey Park
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.